Question explored with the scientific record
the flu vaccine has risks and benefits. Can you provide a cost benefit analysis and whether there are certain people for whom it is not the right choice
The flu vaccine reduces the risk of serious outcomes like hospitalization and death in older adults and people with chronic conditions, but the benefit is modest and varies by season, and the evidence for healthy younger people is much thinner.
The evidence here comes from observational studies, not placebo-controlled trials. That matters because people who get vaccinated tend to be healthier and more careful about their health overall, a bias called the "healthy user effect" [5]. One study in South African elderly found that after full adjustment, the apparent benefit could be explained by this bias alone [5]. Still, the pattern across many studies is consistent.
For people over 65, the data shows a real reduction in all-cause mortality during flu season. A UK study of 24,535 people over 75 found vaccination blunted the rise in deaths when flu was circulating [2]. A Scottish analysis estimated about 732 fewer deaths per flu season after extending vaccination to everyone over 65 [3]. A meta-analysis in diabetics found a 46% lower odds of death with vaccination [1]. For nursing home residents, vaccinating staff reduced resident deaths by about 5 per 100 during flu season in a cluster-randomized trial [4].
The benefit for healthy younger adults is less clear. The vaccine's effectiveness against medically attended flu was only 29% in a recent US season, and just 11% against the dominant H3N2 strain [9]. The main risk is Guillain-Barré syndrome, a rare nerve disorder. The 1976 swine flu vaccine caused about 10 extra cases per million doses [7]. Modern seasonal flu vaccines carry a much smaller risk, about 1 extra case per million [7, 8]. A 2025 VAERS analysis of pediatric quadrivalent flu vaccines found GBS was the only rare event meeting statistical thresholds, with 42 reports across 12 years [8].
| Population | Benefit | Risk |
|---|---|---|
| Over 65 | ~732 fewer deaths/season (Scotland) [3] | GBS ~1 per million doses [7] |
| Diabetics | 46% lower mortality (meta-analysis) [1] | Same GBS risk |
| Nursing home residents | 5 fewer deaths per 100 (staff vaccination) [4] | Same GBS risk |
| Healthy adults under 65 | 29% VE against medically attended flu [9] | Same GBS risk |
| Children (2-6) | 50% VE against flu hospitalization (LAIV) [6] | GBS signal in VAERS, very low absolute risk [8] |
People for whom the vaccine may not be the right choice include those with a history of GBS, those with egg allergy (though the risk is very low at 0.001%) [10], and healthy younger adults who face a very low risk from flu itself. The benefit-risk calculation is most favorable for the elderly and those with chronic conditions, and least favorable for healthy people under 65.
My call: the flu vaccine offers a modest, real benefit for older adults and those with chronic conditions, with a very small risk of serious harm. For healthy younger people, the benefit is marginal and the decision should be individual. Confidence: moderate.
Sources used 10
-
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people
Among 24,535 people aged over 75 in UK primary care, influenza vaccination blunted the rise in all-cause mortality during high influenza circulation; the estimated effectiveness against influenza-associated death was 83%, though imprecise.
DOI: 10.1136/bmj.38198.594109.ae -
Modelling the population effectiveness of the national seasonal influenza vaccination programme in Scotland: The impact of targeting all individuals aged 65 years and over
Using Scottish routine data from 1981-2012, Poisson GAM models estimate that the mid-2000 policy extending influenza vaccination to all people aged 65+ was associated with significant reductions in excess all-cause mortality, cardiovascular and COPD mortality, and COPD hospitali…
DOI: 10.1111/irv.12583 -
Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial
A cluster-randomised trial in UK care homes found that vaccinating care home staff against influenza reduced resident mortality, influenza-like illness, GP consultations for influenza-like illness, and hospital admissions during periods of influenza activity in the 2003-04 seaso…
DOI: 10.1136/bmj.39010.581354.55 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Live‐attenuated influenza vaccine effectiveness against hospitalization in children aged 2–6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14–2015/16
The first three seasons of England's childhood LAIV vaccination program were associated with 50.1% adjusted vaccine effectiveness against laboratory-confirmed influenza hospitalization in 2-6-year-olds, with positive estimates by age group and influenza type, though risk-stratif…
DOI: 10.1111/irv.12990 -
Guillain-Barré Syndrome and Vaccination: Usually Unrelated
A narrative review of epidemiological data on Guillain-Barré syndrome (GBS) and vaccines concludes that GBS is usually triggered by antecedent infections rather than vaccination; clear causal associations were limited to the obsolete neural-tissue rabies vaccine and the 1976 swi…
DOI: 10.1177/001857870003500214 -
Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study
Across 15,458 pediatric VAERS reports (2013-2024), QIVs showed generally favorable safety; only Guillain-Barré syndrome met both disproportionality thresholds, with low absolute risk, and Flucelvax had the lowest SAE rate.
DOI: 10.3389/fped.2025.1640498 -
Update From the Advisory Committee on Immunization Practices
ACIP's June 2019 meeting update reports vaccine policy votes on HPV, pneumococcal, influenza, hepatitis A, and meningococcal vaccines, plus measles, zoster, and dengue vaccine surveillance and trial evidence.
DOI: 10.1093/jpids/piz058 -
Chicken egg allergy and vaccination: Modern approaches
Most vaccines containing egg-derived components are safe for people with chicken egg allergy; measles, mumps, rubella, and influenza vaccines are safe, while yellow fever, rabies, and chickenpox vaccines require caution or alternatives.
DOI: 10.29089/paom/201212